Severe Drug Shortages and Price Hikes Crisis in Iran
Citizens and pharmaceutical associations in Iran report a severe healthcare crisis characterized by drastic medication shortages and price hikes of up to 400 percent. Patients suffering from chronic and critical conditions, including cancer, epilepsy, psychiatric disorders, and organ transplants, face life-threatening interruptions in treatment. Many individuals are forced to visit numerous pharmacies daily without success, driving them toward black markets or ineffective traditional remedies due to the unavailability of prescribed drugs. The situation is exacerbated by insurance companies' failure to settle debts with pharmacies, leading to widespread stockouts. Specific examples include insulin prices reaching 900,000 tomans and cancer drug costs soaring beyond the reach of average pensions. Reports from Tehran, Gilan, and other regions highlight the desperation of families who cannot afford essential medicines like Rapamune or Erbitux. The crisis affects both specialized treatments and general medications, with diagnostic and therapeutic service costs also rising significantly, creating a disastrous environment for public health.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection